107 related articles for article (PubMed ID: 1965755)
41. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
42. Immunohistochemical analysis of estrogen receptors in breast carcinomas using monoclonal antibodies that recognize different domains of the receptor molecule.
Santeusanio G; Mauriello A; Ventura L; Liberati F; Colantoni A; Lasorella R; Spagnoli LG
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):275-84. PubMed ID: 11127919
[TBL] [Abstract][Full Text] [Related]
43. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
Wilbur DC; Barrows GH
Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
[TBL] [Abstract][Full Text] [Related]
44. Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ.
Barnes NL; Boland GP; Davenport A; Knox WF; Bundred NJ
Br J Surg; 2005 Apr; 92(4):429-34. PubMed ID: 15736216
[TBL] [Abstract][Full Text] [Related]
45. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer.
Williams DJ; Cohen C; Darrow M; Page AJ; Chastain B; Adams AL
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):431-6. PubMed ID: 21297447
[TBL] [Abstract][Full Text] [Related]
46. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
Baqai T; Shousha S
Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
[TBL] [Abstract][Full Text] [Related]
47. Changes in intrinsic subtype of breast cancer during tumor progression in the same patient.
Kim C; Lee J; Lee W; Kim A
Int J Clin Exp Pathol; 2015; 8(11):15184-90. PubMed ID: 26823864
[TBL] [Abstract][Full Text] [Related]
48. Anti-estradiol immunoperoxidase labeling of nuclei, not cytoplasm, in paraffin sections, determines estrogen receptor status of breast cancer.
O'Keane JC; Okon E; Moroz K; Burke B; Sheahan K; O'Brien MJ
Am J Surg Pathol; 1990 Feb; 14(2):121-7. PubMed ID: 2154140
[TBL] [Abstract][Full Text] [Related]
49. [Importance of determination of proliferation markers and hormone receptors in breast carcinoma].
Skálová A; Michal M
Cas Lek Cesk; 1997 Jul; 136(15):473-8. PubMed ID: 9340194
[TBL] [Abstract][Full Text] [Related]
50. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
51. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
52. Preliminary study on oncogene product immunohistochemistry (c-erbB-2, c-myc, ras p21, EGFR) in breast pathology.
Saccani Jotti G; Fontanesi M; Bombardieri E; Gabrielli M; Veronesi P; Bianchi M; Becchi G; Bogni A; Tardini A
Int J Biol Markers; 1992; 7(1):35-42. PubMed ID: 1349907
[TBL] [Abstract][Full Text] [Related]
53. Histopathologic characterization of human breast cancer in correlation with estrogen receptor status. A comparison of immunocytochemical and biochemical analysis.
Reiner A; Reiner G; Spona J; Schemper M; Holzner JH
Cancer; 1988 Mar; 61(6):1149-54. PubMed ID: 2830006
[TBL] [Abstract][Full Text] [Related]
54. Does thymidine phosphorylase correlate with angiogenesis in intraductal carcinoma of the breast?
Erkus M; Meteoglu I; Culhaci N; Meydan N; Erdogdu I
Saudi Med J; 2006 Sep; 27(9):1329-33. PubMed ID: 16951768
[TBL] [Abstract][Full Text] [Related]
55. Establishment and characterization of a cell line of human breast carcinoma origin.
Keydar I; Chen L; Karby S; Weiss FR; Delarea J; Radu M; Chaitcik S; Brenner HJ
Eur J Cancer (1965); 1979 May; 15(5):659-70. PubMed ID: 228940
[No Abstract] [Full Text] [Related]
56. [Expression and intranuclear distribution of nucleolin in estrogen receptor-negative and estrogen receptor-positive breast cancers in women measured by laser scanning cytometry].
Masiuk M
Ann Acad Med Stetin; 2006; 52(2):23-32. PubMed ID: 17633394
[TBL] [Abstract][Full Text] [Related]
57. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
58. Correlation of immunocytochemically demonstrated estrogen receptor distribution and histopathologic features in primary breast cancer.
Berger U; Wilson P; McClelland RA; Davidson J; Coombes RC
Hum Pathol; 1987 Dec; 18(12):1263-7. PubMed ID: 2824329
[TBL] [Abstract][Full Text] [Related]
59. Immunohistochemical analysis of breast cancer oestrogen receptor status and its correlation with oestrogen receptor biochemical assay.
Johnston P; Dervan P; McAllister M; Duffy MJ; Carney DN
Ir J Med Sci; 1988 Jul; 157(7):226-8. PubMed ID: 2844691
[No Abstract] [Full Text] [Related]
60. Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes.
Bae MS; Seo M; Kim KG; Park IA; Moon WK
Acta Radiol; 2015 Mar; 56(3):269-75. PubMed ID: 24558165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
